ChemSpider 7981825 Molar mass 454.40 g·mol | Formula C25H25Cl2N3O 3D model (Jmol) Interactive image | |
 | ||
MIN-117 (known formerly as WF-516) is an investigational antidepressant which is under development by Minerva Neurosciences for the clinical treatment of major depressive disorder (MDD). It is described as a 5-HT1A and 5-HT2A receptor antagonist and inhibitor of serotonin and dopamine reuptake, and is also reported to possess affinity for the α1A- and α1B-adrenergic receptors. As of May 2015, MIN-117 is in phase II clinical trials for MDD.
References
MIN-117 Wikipedia(Text) CC BY-SA